Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma by Lièvre, A et al.
Clinicopathological significance of mitochondrial D-Loop
mutations in head and neck carcinoma
A Lie `vre
1, H Blons
1,2, AM Houllier
1, O Laccourreye
3, D Brasnu
3, P Beaune
1,2 and P Laurent-Puig*,1,2
1INSERM, U490, Universite ´ Rene ´ Descartes, Paris F-75006, France;
2Assistance Publique-Ho ˆpitaux de Paris, Ho ˆpital Europe ´en Georges Pompidou,
po ˆle biologie, Paris F-75015, France;
3Assistance Publique-Ho ˆpitaux de Paris, Ho ˆpital Europe ´en Georges Pompidou, service d’Oto-Rhino-Laryngologie
et de Chirurgie cervico-faciale, Paris F-75015, France
Mitochondrial DNA mutations have been reported in several types of tumours, including head and neck squamous cell carcinoma
(HNSCC). The noncoding region of the Displacement-Loop (D-Loop) has emerged as a mutational hotspot and we recently found
that they were associated with prognosis and response to 5 fluorouracil (5FU) in colon cancers. In order to evaluate the frequence
of D-Loop mutations in a large series of HNSCC and establish correlations with clinicopathologic parameters, we sequenced the
D-Loop of 109 HNSCC before a treatment by neoadjuvant 5FU-cisplatin-based chemotherapy and surgery. Then, we correlated
these mutations with prognosis and response to chemotherapy. A D-Loop mutation was identified in 21% of the tumors, the majority
of them were located in a C-tract (D310). The prevalence of D310 mutations increased significantly with the number of cytosines in
the matched normal tissue sequence (P¼0.02). Hypopharyngeal cancer was significantly more frequent (P¼0.03) and tobacco
consumption more important (P¼0.01) in the group of patients with D-Loop mutation. The presence of D-Loop mutation was not
associated with prognosis or with response to neoadjuvant chemotherapy. These results suggest that D-Loop mutations should be
considered as a cancer biomarker that may be useful for the early detection of HNSCC in individuals at risk of this cancer.
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Although much knowledge has been collected concerning
alterations in cancer cell nuclear DNA (nDNA), less attention
has been paid to mutations within mitochondrial DNA (mtDNA).
Mitochondrial DNA is a 16569bp double-stranded, circular DNA
encoding 13 respiratory chain protein subunits, 22 tRNAs and two
rRNAs. It is also composed of a 1.2kb noncoding region, the
Displacement-Loop (D-Loop), which contains essential transcrip-
tion and replication elements. Owing to a particular susceptibility
to oxidative damage due to high levels of reactive oxygen species
(ROS) generation in mitochondria, inefficient DNA repair system
and a lack of protective histones in this organelle, mutation rate
has been reported to be 10–17-fold higher in the mtDNA than in
the nDNA (Fliss et al, 2000). Mitochondria has long been suspected
to be involved in carcinogenesis (Warburg, 1956). Its role in
apoptosis supports this hypothesis (Zamzami and Kroemer, 2001)
and it was shown that mtDNA mutations may lead to a
dysregulation of oxidative phosphorylation that can enhance
production of the carcinogenic ROS. Over last years, somatic
mtDNA mutations have been reported in many human tumours
(Polyak et al, 1998; Maximo et al, 2000; Richard et al, 2000; Yeh
et al, 2000; Hibi et al, 2001b; Sanchez-Cespedes et al, 2001; Kirches
et al, 2001; Liu et al, 2001; Lievre et al, 2005), including head
and neck squamous cell carcinoma (HNSCC) that were found
mutated in small series in 37–77% of the cases (Fliss et al, 2000;
Sanchez-Cespedes et al, 2001; Ha et al, 2002; Tan et al, 2003;
Poetsch et al, 2004). Although mutations may occur throughout
the mitochondrial genome, the vast majority of them have been
described in the noncoding region of the D-Loop and particularly
in a mononucleotide repeat named D310 (C-tract, nucleotide
position: 303–315) that has emerged as a mutational hotspot in
HNSCC (Fliss et al, 2000; Sanchez-Cespedes et al, 2001; Ha et al,
2002; Tan et al, 2003; Poetsch et al, 2004).
Head and neck squamous cell carcinoma represents 5% of all
newly diagnosed cancer cases in the northern and western Europe
and in the US (Muir and Weiland, 1995) where it represents a
public health problem. As in most solid tumours, head and neck
tumor epithelial cells undergo nuclear genetic alterations in proto-
oncogenes and tumour suppressor genes through a multistep
process. One of the most frequent alterations are TP53 somatic
mutations found in more than a half of the cases. Allelic losses are
also frequently observed on 3p, 9p and 17p (Nawroz et al, 1994;
van der Riet et al, 1994; Blons et al, 1999), as the amplification of
the cyclin D1 oncogene. Identification of new genetic alterations
associated with HNSCC is important since they may allow to better
understand the molecular mechanisms involved in head and neck
carcinogenesis and serve as a molecular marker that may be used
in evaluating the tumorigenic potential of head and neck lesions in
individuals at high risk of cancer. Recently, we found that D-Loop
Received 15 December 2005; accepted 17 January 2006; published
online 21 February 2006
*Correspondence: Professor P Laurent-Puig, INSERM U490, Universite ´
Rene ´ Descartes, 45 rue des Saints-Pe `res 75006, Paris, France;
E-mail: pierre.laurent-puig@univ-paris5.fr
British Journal of Cancer (2006) 94, 692–697
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
smutations were linked to prognosis and lack of benefit from 5
fluorouracil (5FU)-based adjuvant chemotherapy in colorectal
carcinomas (Lievre et al, 2005). Neoadjuvant chemotherapy have
been recently developed in new treatment strategies of locally
advanced HNSCC and has been shown to be curative in complete
clinical responder patients with a cancer of the pharyngolarynx
(Laccourreye et al, 2001). Identification of molecular factors
associated with response to neoadjuvant chemotherapy has
become an important goal because it may help to select patients
who could benefit from this treatment and so from a possible
organ preservation. Therefore, the aims of this work were to
determine the frequency of D-Loop mutations in a large series
of HNSCC, establish correlations between D-Loop mutations
and clinicopathologic parameters and determine the impact of
these mutations on prognosis and response to neoadjuvant
5FU–cisplatin-based chemotherapy in HNSCC patients.
MATERIALS AND METHODS
Patients
This study was performed on patients with histologically proven
HNSCC managed at the Laennec Hospital (Paris, France) who had
been prospectively included in a previous study in which response
to neoadjuvant chemotherapy was assessed (Blons et al, 2004). The
inclusion criteria retained were the following: no previous history
of cancer, no multiple tumour locations, no contraindication for a
5FU- or cisplatin-based chemotherapy and indication for neo-
adjuvant chemotherapy prior to surgery or radiotherapy. This work
was performed according to the French Law and blood samples
and tumour biopsies were obtained after written informed consent
and approval of the local ethic committee (CCPPRB-#96,017).
Among the 148 patients initially included, 109 (98 male and 11
female subjects, mean age: 57.871 years) for whom DNA were still
available were screened for mtDNA mutations. Tumours were
located in the oral cavity (n¼13), the oropharynx (n¼46), the
hypopharynx (n¼27) and the endolarynx (n¼23). They were
classified according to the TNM classification and staged as
recommended by the American Joint Committee on Cancer. There
were five T1, 42 T2, 28 T3, 34 T4 tumours, and 49 tumours were N0
whereas 60 of them were Nþ. Three tumours were stage I, 23 were
stage II, 25 were stage III and 58 were stage IV. Among the
patients, 63 smoked 435 pack-years; 34, 15–35 pack-years and 12,
o15 pack-years. A TP53 mutation was present in 72 patients
(67.3%). Clinicopathologic characteristics of the patients are listed
in Table 1. All patients received a neoadjuvant chemotherapy
before surgery or radiotherapy that consisted of cisplatin
(25mgm
 2day
 1) and 5FU (1gm
 2day
 1) delivered as a daily
continuous i.v. dose in 4-day courses. Three courses were repeated
at 16–21 days intervals. Clinical response was assessed as defined
by the Eastern Cooperative Oncology Group. Responder patients
(R) were defined by patients who showed at least a 50% decrease in
tumour size and nonresponder patients (NR) by those who showed
o50% decrease in tumour size. In this series, 72 patients (66.1%)
were responders and 37 (33.9%) were nonresponders.
Tissue sample preparation and DNA extraction
Tumour and 10ml of blood from each patient were collected at the
initial diagnosis during endoscopy under general anesthesia. All
tumour samples were diagnosed as invasive squamous-cell carcino-
ma after a histopathological analysis and then frozen in liquid
nitrogen. Lymphocytes and tumour tissues samples were stored at
 801C and extracted as described previously (Blons et al, 1999).
Displacement-Loop amplification
Polymerase chain reaction (PCR) amplification of the D-Loop was
performed on a Gen Amp PCR System 9700 (Applied Biosystems,
Foster City, CA, USA) using primers F47: 50-CGC ACG GAC TAC
AAC CAC GAC-30 (forward) and R15: 50-CTG TGG GGG GTG
TCT TTG GG (reverse) as described previously (Lievre et al, 2005).
The 2467bp PCR products (nucleotide positions: 14679–577)
were then purified using G-50 Sephadex superfine (Amersham
Biosciences, Orsay, France) on Multiscreen support (Millipore,
Bedford, MA, USA).
Direct sequencing of the D310 repeat
The D310 repeat sequencing was performed on a Gene Amp PCR
System 9700 (Applied Biosystems) using a Big Dye Terminator
cycle sequencing kit (Applied Biosystems) as described previously
(Lievre et al, 2005). Sequences were analysed on an ABI Prism
s
3900 DNA Analyser automated sequencer (Applied Biosystems).
The results of DNA sequence analysis were compared with the
published reference mtDNA sequence (GenBank, access number
J01415) using Autoassembler
s software (Applied Biosystems). A
400bp fragment of the D-Loop (nucleotide position: 190–590)
containing the D310 homopolymeric C-tract from each patient was
analysed. Any mtDNA sequences that differed between tumour
and matched lymphocytes mtDNA were scored as somatic
mutations. All somatic mutations found were further validated
by a new independent amplification and sequencing.
Statistical analysis
The w
2-test was used to determine the relationship between each
categorical variable and D-Loop mutations, and a t-test to
determine the relationship between quantitative variables and
D-Loop mutations. Survival curves were constructed using the
Kaplan–Meier method and compared using the log-rank test. The
Table 1 Clinicopathologic characteristics of HNSCC patients according
to D-Loop mutation
Clinicopathologic
characteristics
Number
of
patients
Patients
with
mutated
tumour (%)
Patients
with
nonmutated
tumour (%) P-value
Age (mean) 56.972 58.071 0.655
Gender
Male 98 (89.9) 22 (95.6) 76 (88.4) 0.3
Female 11 (10.1) 1 (4.4) 10 (11.6)
Tumour sites
Oral cavity 13 (11.9) 1 (4.4) 12 (13.9) 0.03
Oropharynx 46 (42.2) 7 (30.4) 39 (45.4)
Hypopharynx 27 (24.8) 11 (47.8) 16 (18.6)
Endolarynx 23 (21.1) 4 (17.4) 19 (22.1)
Tumour stage
I 3 (2.8) 2 (8.7) 1 (1.2) 0.24
II 23 (21.1) 4 (17.4) 19 (22.1)
III 25 (22.9) 6 (26.1) 19 (22.1)
IV 58 (53.2) 11 (47.8) 47 (54.6)
Tobacco (mean
pack-year)
48733 7 72 0.01
TP53 mutation
Yes 72 (67.3) 19 (82.6) 53 (63.1) 0.07
No 35 (32.7) 4 (17.4) 31 (36.9)
Response to chemotherapy
Responder 72 (66.1) 14 (60.9) 58 (67.4) 0.55
Nonresponder 37 (33.9) 9 (39.1) 28 (32.6)
Total 109 (100) 23 86
HNSCC¼head and neck squamous cell carcinoma; D-Loop¼Displacement-Loop.
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smedian time of survival was used to summarise the survival data.
These statistical tests were performed using the STATA software
(STATA 7.0; College Station, TX, USA). A P-value o0.05 was used
to indicate statistical significance.
RESULTS
Displacement-Loop mutations
Displacement-Loop sequence analysis was performed in 109
patients. A total of 25 somatic D-Loop mutations were identified
in 23 of the 109 (21%) tumours (Table 2). The majority of the
mutations were located in the D310 mononucleotide repeat (19 out
of 25, 76%). These mutations were insertions or deletions of one
(n¼15) to several (n¼4) base pairs. Six mutations were found
outside the D310 sequence. Among them, five were substitution of
one base pair. The last one was a CA deletion at the nucleotide
position 514. Two patients (nos. 22 and 153) had two mutations: in
each of them, a D310 mutation coexisted with a D-Loop mutation
located outside the D310 repeat. Among all mutations, 10 (40%)
were homoplasmic and 15 (60%) were heteroplasmic. Homo-
plasmic mutations were significantly more frequent in the group of
D-Loop mutations located outside the D310 repeat (5/6) than in
the group of D310 mutations (five out of 19) (83 vs 26%, P¼0.02).
The D310 sequence is polymorphic in the human population.
The number of cytosines in the 7-bp tract varied from 6 to 13 and
the most frequent sequences for the D310 region are C7TC6,C 8TC6
and C9TC6. In our series, the D310 sequence in nonmalignant
tumour tissues was homoplasmic in 83.5% and heteoplasmic in
16.5% of the cases and was distributed as follows: C7TC6 in 65 out
of 109 (59.6%), C8TC6 in 20 out of 109 (18.4%), C9TC6 in six out of
109 (5.5%), C8TC6/C9TC6 in 17 out of 109 (15.6%) and C9TC6/
C10TC6 in one out of 109 (0.9%). The prevalence of tumour D310
mutations increased significantly with the number of cytosines in
the matched normal tissue sequence. Indeed, the C7TC6 sequence
was altered in eight patients out of the 65 (12%), the C8TC6 and
C8TC6/C9TC6 sequences were altered in 12 patients out of the 37
(32%) and the C9TC6 and C9TC6/C10TC6 sequences were altered in
three out of the seven cases (43%) (P¼0.02).
A total of 24 germline polymorphisms were found (Table 3).
Twenty-one were already reported in the MITOMAP database and
three of them (A240G, A249G and C534T) are novel.
Association of D-Loop mutations and clinicopathologic
characteristics
The analysis of clinicopathologic variables showed a significant
difference in tumour site between tumours with and without
D-Loop mutation (P¼0.03). Indeed, among D-Loop-mutated
tumours, 47.8% were located in the hypopharynx as compared to
18.6% in the group of nonmutated tumours (Table 1). Moreover,
presence of D-Loop mutation was significantly associated with
tobacco consumption: the mean number of pack-year in the group
of patients with tumour D-Loop mutation was 4873 compared to
3772 for patients without mutation (P¼0.01). The analysis of
other clinicopathologic variables showed no correlation between
the presence of a tumour D-Loop mutation and, respectively, age,
gender, tumour stage and TP53 mutation (Table 1).
Association of D-Loop mutations and response
to chemotherapy and survival
Tumours were classified according to the decrease in tumour size
after 5FU–cisplatin-based chemotherapy as it was defined in the
Materials and Methods section. In all, 72 patients (66.1%) were
Table 2 Summary of D-Loop somatic mutations found in the 109
HNSCC patients
Patients
number
Nucleotide
position DNA (N-T)
a
MtDNA
mutation status
16 303–309 C7-C7/C9 Heteroplasmy
22 214 A-G Homoplasmy
303–309 C8/C9-C8 Homoplasmy
23 514 (CA)5-(CA)4 Homoplasmy
28 314 C-T Homoplasmy
32 303–309 C8-C7 Homoplasmy
42 303–309 C7-C7/C9 Heteroplasmy
43 303–309 C8/C9-C8/C10 Heteroplasmy
48 303–309 C8-C7/C8 Heteroplasmy
53 303–309 C8-C8/C9 Heteroplasmy
63 303–309 C8/C9-C8 Homoplasmy
82 303–309 C9/C10-C9 Homoplasmy
110 303–309 C7-C6/C7 Heteroplasmy
114 303–309 C8/C9-C9/C10 Heteroplasmy
118 213 A-G Homoplasmy
127 303–309 C8-C8/C9 Heteroplasmy
141 303–309 C9-C8 Homoplasmy
146 408 T-A Heteroplasmy
153 239 C-T Homoplasmy
303–309 C7-C9/C10 Heteroplasmy
155 303–309 C8/C9-C9 Heteroplasmy
161 303–309 C8-C7/C8 Heteroplasmy
167 303–309 C8/C9-
complex
Heteroplasmy
180 303–309 C9-C8/C9 Heteroplasmy
206 303–309 C8-C8/C9 Heteroplasmy
aN¼normal tissue; T¼tumour tissue. HNSCC¼head and neck squamous cell
carcinoma; D-Loop¼Displacement-Loop.
Table 3 Summary of the germline polymorphisms found in the 109 head
and neck squamous cell carcinoma patients
Patients number
Nucleotide
substitution
Nucleotide
position
Reported
polymorphism
(database
a)
16, 53 G-A 200 Yes
20, 48, 206 T-C 204 Yes
48, 206 G-A 207 Yes
27, 32, 52, 128, 150 G-A 228 Yes
82 T-C 239 Yes
199 A-G 240 Novel
41, 54, 171 C-T 242 Yes
133 A-G 249 Novel
48 T-C 250 Yes
44 A-G 257 Yes
171 C-T 295 Yes
9, 13, 18, 26, 31, 35, 65, 72,
76, 84, 87, 88, 116, 164,
169, 177, 183, 190
C7-C8 303–309 Yes
20, 133, 156, 159 C7-C9 303–309 Yes
22 C-T 456 Yes
28, 32, 41, 52, 54, 128, 171 C-T 462 Yes
44, 119 T-C 477 Yes
28, 32, 41, 52, 54, 128, 171,
172
T-C 489 Yes
26, 83, 194, 208 C-T 497 Yes
47 A-C 512 Yes
23, 32, 71, 72, 83, 130, 146,
172, 195
(CA)5-
(CA)4
514 Yes
192 (CA)5-
(CA)6
514 Yes
9, 22 (CA)5-
(CA)7
514 Yes
65 A-G 533 Yes
165 C-T 534 Novel
aMITOMAP database available on web: www.mitomap.org.
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sresponders and 37 (33.9%) were nonresponders. No correlation
was found between the presence of tumour D-Loop mutation and
response to neoadjuvant chemotherapy (Table 1).
The presence of D-Loop mutation was not a prognostic factor:
the 5-year overall survival of patients with tumour D-Loop
mutation was 81% compared to 70% for patients without mutation
(P¼0.71, Figure 1).
DISCUSSION
In the past few years, somatic mtDNA mutations have been
identified in several types of human tumours (Polyak et al, 1998;
Fliss et al, 2000; Maximo et al, 2000; Richard et al, 2000; Yeh et al,
2000; Hibi et al, 2001b; Kirches et al, 2001; Liu et al, 2001; Sanchez-
Cespedes et al, 2001; Nomoto et al, 2002; Lievre et al, 2005),
including HNSCC (Fliss et al, 2000; Sanchez-Cespedes et al, 2001;
Ha et al, 2002; Poetsch et al, 2004). In the present study, which is
the largest series of HNSCC analysed for mtDNA mutations in
the literature, we report a 21% frequency of D-Loop somatic
mutations. This frequency is similar to that obtained by Fliss et al
(2000) who performed a sequence analysis of 80% of the
mitochondrial genome and found a D-Loop mutation in three of
13 (23%) HNSCC patients. However, other studies on small series
of patients reported more frequent D-Loop mutations, ranging
from 37 to 61% (Sanchez-Cespedes et al, 2001; Ha et al, 2002;
Poetsch et al, 2004) of the cases. In these studies, D310 repeat
emerged as a mutational hotspot. On 67 primary HNSCC from 56
patients, Poetsch et al (2004) sequenced two parts of the D-Loop
and two mitochondrial genes (MTND1 and MTND5). They found
all mtDNA mutations in a part of the D-Loop and a mtDNA
microsatellite instability, defined as insertions or deletions in the
D310 repeat, in 42% of the tumours. Another study showed 66% of
D-Loop mutations in 18 oral cancers of betel quid chewers (Tan
et al, 2003), which however cannot be really assimilated to HNSCC
of tobacco and alcohol consumers. The vast majority of these
mutations were located between nucleotides 204 and 489 and 44%
of the tumours harboured mutations in the D310 repeat. These
results led us to focus our sequence analysis on a 400bp fragment
of the D-Loop (nucleotide position: 190–490) containing the D310
C-tract which was found to be a hotspot of mutations since more
than 80% of the D-Loop mutations were located in this sequence,
as it was suggested previously (Sanchez-Cespedes et al, 2001; Ha
et al, 2002). The differences in D-Loop mutation frequency
observed between our study, that of Fliss et al and the other
studies remain to be explained. Overestimation of gene mutation
rates is frequently observed in series of small sample size, which is
the case of previous studies that have specifically addressed the
D-Loop mutation frequency issue in HNSCC. As a consequence,
our study gives new information as regards to the frequency of
D-Loop mutations in HNSCC that has likely been overestimated in
previous studies of small samples size. Another explanation may
be differences in distribution of tumour sites between studies. We
showed that tumours located in the hypopharynx (24.8% of all
tumours) were significantly more mutated than tumours in other
sites. Proportion of hypopharynx tumours is not known in the
other studies (Fliss et al, 2000; Sanchez-Cespedes et al, 2001; Ha
et al, 2002; Poetsch et al, 2004). So, we can speculate that a higher
proportion of tumours located in the hypopharynx would be
associated with a higher frequency of mtDNA mutation. Moreover,
in the present study, the prevalence of tumour D310 mutations
increased significantly with the number of cytosines in the D310
sequence of matched normal tissues. According to these findings,
the frequency of D-Loop mutations may depend on the propor-
tion of the different D310 sequences in the normal tissues
(C7 8 9 10TC6), which is probably not the same in the different
studies. Finally, the mtDNA mutagenesis process in oral squamous
cell carcinoma of betel quid chewers is likely to be different to that
of cigarettes smokers. Betel quid contains tender areca nuts and
lime that have been shown to generate ROS and induce oxidative
DNA damage (Nair et al, 1987; Stich and Anders, 1989), which can
initiate or promote oral carcinogenesis. These betel quid
compounds could therefore preferentially target mtDNA, which
may explain the high proportion of oral tumours with mtDNA
mutation observed in betel quid chewers (Tan et al, 2003),
compared to that observed in cigarette smokers.
With a frequency of more than 20% in HNSCC, D-Loop
mutations may be an interesting molecular marker in the
evaluation of the tumorigenic potential of head and neck lesions
in individuals at high risk of this cancer. They were shown to be an
early event in head and neck carcinogenesis (Ha et al, 2002). Their
frequence was 22% in the earliest head and neck premalignant
lesions and increased with the degree of dysplasia to reach 50% in
lesions of severe dysplasia and 61% in carcinomas in situ in a
recent study (Ha et al, 2002). Similar results were obtained in
prostate (Jeronimo et al, 2001) and oesophagus adenocarcinoma
(Miyazono et al, 2002) where identical D-Loop mutations were
found both in primary tumours and corresponding premalignant
lesions, which is consistent with a process of clonal evolution.
These data suggest that D-Loop mutations could be considered as
a cancer biomarker that may be useful for the early detection of
HNSCC. It is all the more important since mtDNA mutations were
reported to be easily detectable in bodily fluids and serum of
cancer patients (Fliss et al, 2000; Hibi et al, 2001a; Jeronimo et al,
2001; Parrella et al, 2001; Nomoto et al, 2002). As a consequence,
it would be interesting to search for D-Loop mutations in saliva
and serum of a large series of HNSCC patients in order to evaluate
their relevance in association with other tumour-specific
molecular alterations in the screening of this cancer in alcohol
and tobacco consumers.
We analysed for the first time the correlation between mtDNA
mutations and clinicopathologic characteristics in a series of
HNSCC patients. We found that tobacco consumption was
significantly more important in the group of patients with tumour
D-Loop mutation than in those without mutation. It is not very
surprising since cigarette smoke contains several mutagenic
ROS-forming subtances and carcinogens that can cause DNA
damages, especially in mtDNA that has been proved to be more
susceptible to oxidative damages than nDNA (Marcelino and
Thilly, 1999). In the same way, mtDNA content alterations have
been recently shown to be associated with smoking (Ballinger et al,
1996; Lee et al, 1998). Our results also show an association between
tumour site and D-Loop mutation, demonstrating that hypo-
pharyngeal tumours were significantly more frequent in the group
of mutated tumours compared to that of nonmutated tumours.
This association remains unclear. One explanation could be a
difference in exposition degree to mtDNA mutagenic agents
between hypopharynx and other tumour sites. It was shown a
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Figure 1 Overall survival curves of HNSCC patients with and without
tumour D-Loop mutation.
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ssignificant higher risk for cancer of the hypopharynx than for
larynx cancer with alcohol drinking, which may be explained by
the fact that hypopharynx enters in contact with the bolus
(alcohol) and the air (tobacco smoke) while air pass through
larynx but not the bolus (Esteve et al, 1996; Menvielle et al, 2004).
Alcohol is known to cause oxidative stress through production of
ROS (Hoek et al, 2002) and ethanol consumption has been
reported to induce oxidative damage to mtDNA with increased
levels of 8-hydroxydeoxyguanosin in rats (Cahill et al, 1997). The
abasic sites and oxidised bases generated could so be responsible
for mtDNA mutations. We did not found any correlation
between D-Loop mutation and gender. This may be explained by
the disequilibrium between the group of male (n¼98) and female
(n¼11) subjects. A better distribution between gender would
have been desirable but is not possible to obtain in practice since
the sex ratio currently observed in France for HNSCC is
approximately M:7/F:1.
In the present study, our first intention was not to investigate
the prognostic value of D-Loop mutations and their association
with response to chemotherapy, but to evaluate their role as a
biomarker of HNSCC by determining the real frequency in HNSCC
and their potential correlation with clinicopathologic parameters.
However, neoadjuvant chemotherapy has been recently developed
in locally advanced HNSCC because conventional treatments with
radiotherapy and surgery do not always control them, are
associated with profound functional morbidity and often result
in physical and psychological suffering. Cisplatin and 5FU
combination, which is the standard regimen in this case, has
shown objective response rates of 71%, with complete response
rates of 18% (Altundag et al, 2005). This neoadjuvant chemo-
therapy do not improve survival but is of interest in terms of organ
preservation strategies in responder patients (Laccourreye et al,
1999) and has been shown to be curative in complete clinical
responder patients with a cancer of the pharyngolarynx (Laccour-
reye et al, 2001). Therefore, identification of factors linked to
response to neoadjuvant chemotherapy in HNSSC may help in the
selection of patients who could benefit from an organ preservation.
Some studies have revealed that the drug-resistance phenotype can
be significantly associated with resistance to apoptosis induced by
drugs (Landowski et al, 1997). Mitochondria is known to play a
pivotal role in apoptosis (Green and Kroemer, 2004), and it was
suggested that mtDNA determines the cellular response to some
cancer therapeutic agents through a mechanism that could be an
apoptosis modulation (Singh et al, 1999; Hail et al, 2001). We
recently found that D-Loop mutations were associated with poor
prognosis and absence of benefit from adjuvant 5FU chemo-
therapy in colon cancers (Lievre et al, 2005). Given these results, as
all patients in our study received a neoadjuvant chemotherapy
with 5FU–cisplatin, we investigated the association between D-
Loop mutations and response to this treatment. No association
with prognosis or with response to 5FU-cisplatin was found. These
results suggest that mtDNA do not play the same role in the
cytotoxicity of these two anticancer drugs. As 5FU interferes with
the apoptotic process (Sakaguchi et al, 1994), we hypothesised in
our previous study (Lievre et al, 2005) that the potential
respiratory chain alteration induced by D-Loop mutations could
explain in part the absence of benefit from 5FU we observed. On
the contrary, Liang et al demonstrated that mtDNA depletion
increased the sensitivity of cisplatin–induced apoptosis in U937
cells when compared to parental controls containing mtDNA
(Liang and Ullyatt, 1998). According to these findings, we can
speculate that D-Loop mutations may lead both to resistance to
5FU and increased sensitivity to cisplatin, which may explain that
no link was observed between these mutations and response to the
combined therapy in the present study. However, the power of our
study remains low as regards to the small sample size and the
unequal distribution of patients into the two groups considered for
the analysis (23 tumours with D-Loop mutations, 86 tumours
without), and larger studies are needed to confirm this result.
In conclusion, our data suggest that D-Loop mutations should
be considered as a cancer biomarker that may be useful for the
early detection of HNSCC in individuals at risk of this cancer. The
presence of these mutations in saliva and serum of tobacco and
alcohol consumers should be investigated in further studies in
order to evaluate their relevance in the screening of these cancers
in association with other tumour-specific molecular alterations.
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